| Cash flow (USD) | FY 2025 ended Dec 31, 2025 | FY 2024 ended Dec 31, 2024 | FY 2023 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Net income | 4.23B | 4.28B | 4.86B | 11.84B | 11.54B | 4.62B |
| Depreciation and amortization | 762.00M | 764.00M | 752.00M | 778.00M | 803.00M | 666.00M |
| Stock-based compensation | 955.00M | 911.00M | 747.00M | 671.00M | 692.00M | 753.00M |
| Cash from operations | 19.03B | 18.81B | 22.84B | 24.94B | 22.78B | 17.59B |
| Capital expenditure | -1.21B | -974.00M | -777.00M | -695.00M | -787.00M | -798.00M |
| Free cash flow | 17.82B | 17.83B | 22.06B | 24.25B | 21.99B | 16.79B |
| Acquisitions | -204.00M | -17.49B | 0 | -255.00M | -525.00M | -38.26B |
| Cash from investing | -6.64B | -20.82B | -2.01B | -623.00M | -2.34B | -37.56B |
| Dividends paid | -11.66B | -11.03B | -10.54B | -10.04B | -9.26B | -7.72B |
| Share buybacks | -980.00M | -1.71B | -1.97B | -1.49B | -934.00M | -978.00M |
| Net debt issued | 3.99B | 16.96B | 2.00B | 1.00B | 3.00B | |
| Cash from financing | -12.72B | -5.21B | -17.22B | -24.80B | -19.04B | -11.50B |
| Net change in cash | -295.00M | -7.29B | 3.61B | -545.00M | 1.30B | -31.48B |
From AbbVie's 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.